{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:25:00Z","timestamp":1784291100997,"version":"3.55.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Prostate carcinoma (PC) is the most common cancer in men worldwide. However, brain metastases (BM) from prostate cancer are extremely rare events, usually in the later course of the disease. There is no established standard of care treatment for this situation. The efficacy of androgen synthesis inhibitor abiraterone in BM from PC is unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case<\/jats:title><jats:p>We herein report the case of an 83-year-old patient with metastatic hormone-sensitive PC who had multiple BM at primary diagnosis, clinically manifesting with dizziness, ataxia, and unsteady gait. Combination of abiraterone and androgen deprivation therapy showed exceptional sustained cerebral tumor response. After 12 months of treatment, the patient is asymptomatic with an excellent performance status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Symptomatic BM from PC is a rarity but can show sustained response to abiraterone and androgen deprivation therapy. After comprehensive literature search, there is no comparable case published to date.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1555897","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T04:10:37Z","timestamp":1744344637000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Abiraterone in brain metastases from prostate cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Tobias","family":"Peres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Aeppli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rothermundt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22742","article-title":"Distribution of metastatic sites in patients with prostate cancer: A population-based analysis","volume":"74","author":"Gandaglia","year":"2014","journal-title":"Prostate"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5152\/tud.2018.74555","article-title":"Brain metastases from prostate cancer: A single-center experience","volume":"45","author":"Kany\u0131lmaz","year":"2018","journal-title":"Turk J Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1552-6569.2012.00767.x","article-title":"Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis","volume":"24","author":"Hatzoglou","year":"2014","journal-title":"J Neuroimaging"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11060-004-8093-6","article-title":"Brain metastases: epidemiology and pathophysiology","volume":"75","author":"Gavrilovic","year":"2005","journal-title":"J Neurooncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.2587","article-title":"Three cases of brain metastasis from castration-resistant prostate cancer","volume":"8","author":"Shida","year":"2019","journal-title":"Clin Case Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2020.07.012","article-title":"Prostate cancer central nervous system metastasis in a contemporary cohort","volume":"19","author":"Boxley","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-012-0994-1","article-title":"Frequency of brain metastases from prostate cancer: an 18-year single-institution experience","volume":"111","author":"Caffo","year":"2013","journal-title":"J Neurooncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2019.100879","article-title":"Solitary brain metastasis from prostate cancer after multi modality treatment: A case report","volume":"24","author":"Ishizaki","year":"2019","journal-title":"Urol Case Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1673.2008.01973.x","article-title":"Increased detections of leptomeningeal presentations in men with hormone refractory prostate cancer: an effect of improved systemic therapy","volume":"52","author":"Lin","year":"2008","journal-title":"J Med Imaging Radiat Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2022.04.004","article-title":"Impact of novel hormonal agents (Abiraterone, enzalutamide) on the development of visceral and\/or brain metastases in patients with bone-metastatic castration-resistant prostate cancer","volume":"20","author":"Pobel","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11522","article-title":"Brain metastasis from prostate carcinoma: The M. D. Anderson Cancer Center experience","volume":"98","author":"Tremont-Lukats","year":"2003","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2020.02.152","article-title":"Prostate cancer brain metastases: A single-institution experience","volume":"138","author":"Bhambhvani","year":"2020","journal-title":"World Neurosurg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5324600","article-title":"The clinical, diagnostic, therapeutic, and prognostic characteristics of brain metastases in prostate cancer: A systematic review","volume":"2022","author":"Mirmoeeni","year":"2022","journal-title":"Prostate Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11144165","article-title":"Prostate cancer brain metastasis: review of a rare complication with limited treatment options and poor prognosis","volume":"11","author":"Rajeswaran","year":"2022","journal-title":"J Clin Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991201)86:11<2301::AID-CNCR18>3.0.CO;2-D","article-title":"Brain metastasis from prostate carcinoma: antemortem recognition and outcome after treatment","volume":"86","author":"McCutcheon","year":"1999","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3309","article-title":"Aggressive variants of castration-resistant prostate cancer","volume":"20","author":"Beltran","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 advanced prostate cancer consensus conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2018.08.018","article-title":"Isolated brain metastasis of prostate carcinoma in the setting of normal prostate specific antigen","author":"Campagna","year":"2018","journal-title":"Urol Case Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-017-2460-6","article-title":"Radiotherapy for cranial and brain metastases from prostate cancer: a systematic review","volume":"133","author":"Sita","year":"2017","journal-title":"J Neurooncol"},{"key":"B23","article-title":"Brain metastasis from prostate cancer. Report of 13 cases and critical analysis of the literature","volume":"24","author":"Salvati","year":"2005","journal-title":"J Exp Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.02.033","article-title":"Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies","volume":"46","author":"Gril","year":"2010","journal-title":"Eur J Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1489-y","article-title":"Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients","volume":"37","author":"Van der Veldt","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11095-014-1442-z","article-title":"Breast cancer resistance protein (BCRP\/ABCG2) and P-glycoprotein (P-GP\/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699)","volume":"32","author":"Durmus","year":"2015","journal-title":"Pharm Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163","article-title":"Restricted delivery of talazoparib across the blood-brain barrier limits the sensitizing effects of PARP inhibition on temozolomide therapy in glioblastoma","volume":"16","author":"Kizilbash","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40169-019-0247-4","article-title":"Sites of synchronous distant metastases and prognosis in prostate cancer patients with bone metastases at initial diagnosis: a population-based study of 16,643 patients","volume":"8","author":"Zhao","year":"2019","journal-title":"Clin Transl Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S64940","article-title":"Preclinical profile of cabazitaxel","volume":"8","author":"Vrignaud","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v2.i6.228","article-title":"Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports","volume":"2","author":"De Placido","year":"2014","journal-title":"World J Clin Cases"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1029-9","article-title":"Enzalutamide: A review in castration-resistant prostate cancer","volume":"78","author":"Scott","year":"2018","journal-title":"Drugs"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01194-x","article-title":"Apalutamide: A review in non-metastatic castration-resistant prostate cancer","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.326","article-title":"Significant localized reduction in cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide (ENZA) compared to darolutamide (DARO) and placebo (PBO) in healthy volunteers","volume":"2020","author":"Williams","year":"2020","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.156","article-title":"Higher blood\u2013brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography","volume":"37","author":"Zurth","year":"2019","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0403-6","article-title":"Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide","volume":"55","author":"Benoist","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.uct.2007.10.006","article-title":"Development of abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor as a secondary hormonal therapy in prostate cancer","volume":"2","author":"Aggarwal","year":"2007","journal-title":"Cancer Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601879","article-title":"Hormonal impact of the 17alpha-hydroxylase\/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer","volume":"90","author":"O\u2019Donnell","year":"2004","journal-title":"Br J Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30040332","article-title":"Triplet therapy in metastatic castrate sensitive prostate cancer (mCSPC)-A potential new standard of care","volume":"30","author":"Mittal","year":"2023","journal-title":"Curr Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3921","article-title":"Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel","volume":"36","author":"Harshman","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1555897\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T04:10:39Z","timestamp":1744344639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1555897\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":40,"alternative-id":["10.3389\/fonc.2025.1555897"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1555897","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"article-number":"1555897"}}